GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VioQuest Pharmaceuticals Inc (OTCPK:VOQP) » Definitions » Net Current Asset Value

VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Net Current Asset Value : $-1.05 (As of Jun. 2008)


View and export this data going back to . Start your Free Trial

What is VioQuest Pharmaceuticals Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

VioQuest Pharmaceuticals's net current asset value per share for the quarter that ended in Jun. 2008 was $-1.05.

The historical rank and industry rank for VioQuest Pharmaceuticals's Net Current Asset Value or its related term are showing as below:

VOQP's Price-to-Net-Current-Asset-Value is not ranked *
in the Biotechnology industry.
Industry Median: 3.69
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

VioQuest Pharmaceuticals Net Current Asset Value Historical Data

The historical data trend for VioQuest Pharmaceuticals's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VioQuest Pharmaceuticals Net Current Asset Value Chart

VioQuest Pharmaceuticals Annual Data
Trend Dec98 Dec99 Dec00 Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 1.53 1.04 0.51 -0.83

VioQuest Pharmaceuticals Quarterly Data
Sep03 Dec03 Mar04 Jun04 Sep04 Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.40 -0.83 -1.23 -1.05

Competitive Comparison of VioQuest Pharmaceuticals's Net Current Asset Value

For the Biotechnology subindustry, VioQuest Pharmaceuticals's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VioQuest Pharmaceuticals's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VioQuest Pharmaceuticals's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where VioQuest Pharmaceuticals's Price-to-Net-Current-Asset-Value falls into.



VioQuest Pharmaceuticals Net Current Asset Value Calculation

VioQuest Pharmaceuticals's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2007 is calculated as

Net Current Asset Value Per Share(A: Dec. 2007 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1.308-5.843-0-0)/5.46211
=-0.83

VioQuest Pharmaceuticals's Net Current Asset Value (NCAV) per share for the quarter that ended in Jun. 2008 is calculated as

Net Current Asset Value Per Share(Q: Jun. 2008 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1.132-6.848-0-0)/5.46164
=-1.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


VioQuest Pharmaceuticals  (OTCPK:VOQP) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


VioQuest Pharmaceuticals Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of VioQuest Pharmaceuticals's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 2287, Minneapolis, MN, USA, 55402
Website
VioQuest Pharmaceuticals Inc is a biopharmaceutical company focused on the acquisition, development and commercialization of clinical stage drug therapies targeting both the molecular basis of cancer and side effects of cancer treatment.
Executives
Mark D Dacko director, officer: CFO and Secretary 800 NICOLLET MALL SUITE 2690, MINNEAPOLIS MN 55402
Christopher P. Schnittker officer: V.P. & Chief Financial Officer 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Brian Lenz officer: CFO and Treasurer 65 COMMERCE WAY, HACKENSACK NJ 07601
Lau Johnson Yiu Nam director
Michael Weiser director C/O SPACES, SUITE 265, 3350 VIRGINIA STREET, MIAMI FL 33133
Stephen Rocamboli director, officer: Secretary C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019
Daniel E Greenleaf director, officer: President and CEO C/O NABI BIO PHARMACEUTICALS, 5800 PARK OF COMMERCE BLVD., N.W., BOCA RATON FL 33487
Lester E Lipschutz 10 percent owner WOLF BLOCK SCHORR AND SOLIS COHEN, 1650 ARCH STREET, PHILADELPHIA PA 19103
David M Tanen director TWO RIVER GROUP HOLDINGS, LLC., 689 FIFTH AVENUE, NEW YORK NY 10022

VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Headlines

No Headlines